A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8+ T-cell responses by DNA vaccination

Stifter, Katja; Dekhtiarenko, Iryna; Krieger, Jana; Tissot, Alain C.; Seufferlein, Thomas; Wagner, Martin; Schirmbeck, Reinhold

doi:10.1016/j.vaccine.2020.04.003

Cited by 9 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been shown that oncolytic virus plasmids have the capability of coding for PD-L1 inhibitors themselves, allowing for neoantigen recognition by T cells [80]. Additional experiments have tested the efficacy of linking neoantigen peptides to diphtheria toxin and HBV platforms with varying results [81,82].…”

Section: Immune Primingmentioning

confidence: 99%

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies

et al. 2022

View full text Add to dashboard Cite

Alternatives to conventional cancer treatments are highly sought after for high-risk malignancies that have a poor response to established treatment modalities. With research advancing rapidly in the past decade, neoantigen-based immunotherapeutic approaches represent an effective and highly tolerable therapeutic option. Neoantigens are tumor-specific antigens that are not expressed in normal cells and possess significant immunogenic potential. Several recent studies have described the conceptual framework and methodologies to generate neoantigen-based vaccines as well as the formulation of appropriate clinical trials to advance this approach for patient care. This review aims to describe some of the key studies in the recent literature in this rapidly evolving field and summarize the current advances in neoantigen identification and selection, vaccine generation and delivery, and the optimization of neoantigen-based therapeutic strategies, including the early data from pivotal clinical studies.

show abstract

Section: Immune Primingmentioning

confidence: 99%

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In this study, the researchers constructed a Db/Sp244-252/R251H neoantigen epitope (changing an amino acid site) in the EndoB2-Sp protein and found that a single injection of the EndoB2-Sp expression vector into C57Bl/6j mice could effectively induce activation of IFN-γ+CD8+ T cells specifically targeting the neoantigen epitope (Db/Sp244-252/R251H). The expression of Db/Sp244-252/R251H within the core antigen of assembly deficient HBV induced a considerable number of CD8+ T cells specifically targeting Db/Sp244-252/R251H compared with the EndoB2-Sp vaccine[ 53 ]. Zhang et al [ 54 ] used the low-toxicity cholesterol-modified antimicrobial peptide DP7 (DP7-C), which has dual functions as a carrier and an immune adjuvant, to improve dendritic cell (DC)-based vaccine efficacy.…”

Section: Application Of Hcc Neoantigens As Targets In Immunotherapymentioning

confidence: 99%

Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma

Chen¹,

Fang²,

Chen³

et al. 2021

WJGO

View full text Add to dashboard Cite

Tumor-specific neoantigens, which are expressed on tumor cells, can induce an effective antitumor cytotoxic T-cell response and mediate tumor regression. Among tumor immunotherapies, neoantigen vaccines are in early human clinical trials and have demonstrated substantial efficiency. Compared with more neoantigens in melanoma, the paucity and inefficient identification of effective neoantigens in hepatocellular carcinoma (HCC) remain enormous challenges in effectively treating this malignancy. In this review, we highlight the current development of HCC neoantigens in its generation, screening, and identification. We also discuss the possibility that there are more effective neoantigens in hepatitis B virus (HBV)-related HCC than in non-HBV-related HCC. In addition, since HCC is an immunosuppressive tumor, strategies that reverse immunosuppression and enhance the immune response should be considered for the practical exploitation of HCC neoantigens. In summary, this review offers some strategies to solve existing problems in HCC neoantigen research and provide further insights for immunotherapy.

show abstract

A comprehensive comparison of molecular and phenotypic profiles between hepatitis B virus (HBV)-infected and non-HBV-infected hepatocellular carcinoma by multi-omics analysis

Wu,

Dong,

Luo

et al. 2024

Genomics

View full text Add to dashboard Cite

A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8+ T-cell responses by DNA vaccination

Cited by 9 publications

References 67 publications

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies

Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma

A comprehensive comparison of molecular and phenotypic profiles between hepatitis B virus (HBV)-infected and non-HBV-infected hepatocellular carcinoma by multi-omics analysis

Contact Info

Product

Resources

About